Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
TLSA
TLSA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TLSA News
Tiziana Life Sciences Publishes Intranasal Foralumab Study, Highlighting Efficacy Potential
Jan 21 2026
NASDAQ.COM
Tiziana Life Sciences Publishes Positive Study Results for Intranasal Foralumab in MS Patients
Jan 20 2026
Newsfilter
Tiziana Life Sciences Closes Direct Offering of 7.04 Million Shares, Raising $8.8 Million
Jan 16 2026
Globenewswire
Tiziana Life Sciences Closes $8.8 Million Direct Offering of 7.04 Million Shares
Jan 16 2026
Newsfilter
Tiziana Life Sciences (TLSA) Completes $8M Direct Offering with Strong Management Participation
Jan 16 2026
seekingalpha
Plus Therapeutics Prices Public Offering, Raising $15 Million
Jan 15 2026
NASDAQ.COM
Tiziana to Present Clinical Progress of Foralumab at Neuroscience Innovation Forum
Jan 09 2026
Globenewswire
Tiziana Submits 37.4 Patient-Years Safety Report for Foralumab, Highlighting Safety Profile
Dec 29 2025
Globenewswire
Tiziana Submits 37.4 Patient-Years Safety Report for Intranasal Foralumab
Dec 29 2025
Newsfilter
Tiziana's Founder Acquires 97,687 Shares, Boosting Holdings to 36.08% of Capital
Dec 19 2025
Globenewswire
Tiziana Life Sciences Founder Acquires 97,687 Shares, Boosting Stake to 36.08%
Dec 19 2025
Newsfilter
Tiziana Rings Nasdaq Closing Bell Celebrating Foralumab Advancements
Dec 17 2025
Globenewswire
Tiziana Rings Nasdaq Closing Bell Celebrating Foralumab Advancements
Dec 17 2025
Newsfilter
Tiziana CEO Ivor Elrifi Purchases 163,400 Shares, Signaling Confidence
Dec 15 2025
Globenewswire
Tiziana Life Sciences Withdraws Planned Public Offering
Dec 15 2025
NASDAQ.COM
Tiziana Initiates Alzheimer's Trial with First Patient Dosing Next Week
Dec 12 2025
Newsfilter
Show More News
